Suthisisang Chuthamanee, Poolsup Nalinee, Kittikulsuth Wararat, Pudchakan Phutsadee, Wiwatpanich Pichamon
Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Ann Pharmacother. 2007 Nov;41(11):1782-91. doi: 10.1345/aph.1K121. Epub 2007 Sep 18.
Nonsteroidal antiinflammatory drugs such as aspirin and ibuprofen have been shown to be effective in treating migraine.
To evaluate the efficacy of low-dose ibuprofen for treatment of acute migraine attack.
Clinical trials were identified through electronic searches (MEDLINE, EMBASE, EBM review, and the Cochrane Library) up to November 2006 and historical searches of relevant articles. Studies were included if they (1) were double-blind, randomized, placebo-controlled trials that evaluated ibuprofen tablets in moderate or severe migraine attacks in patients greater than 16 years of age, (2) evaluated at least one migraine attack, and (3) reported headache relief, pain-free, sustained pain-free, or relief of other migraine-associated symptoms at 2 hours. The MeSH search terms used were migraine disorders, headache, vascular headache, ibuprofen, adult, and clinical trial. This was followed by a key word search using migraine, cephalalgia, and cephalgia as key words. The reference lists of relevant articles were also scanned to identify possible published trials. There was no language restriction. Two authors extracted data independently. Disagreements were resolved through discussion.
Ibuprofen 200 and 400 mg were more effective than placebo in reducing pain intensity and eliminating pain (pain-free) within 2 hours in adults with moderate or severe migraine attacks. For the 200 mg dose, the number needed to treat was 8 (95% CI 5 to 20) for headache relief and 13 (95% CI 8 to 50) for pain-free. The risk ratios for headache relief and pain-free were 1.89 (95% CI 1.45 to 2.46; p < 0.0001) and 2.15 (95% CI 1.24 to 3.73; p = 0.0063), respectively, for ibuprofen 400 mg. The 24-hour sustained pain-free outcome with ibuprofen was no better than with placebo. Ibuprofen 400 mg increased the chance of relief in photophobia and phonophobia by 30% (95% CI 8 to 57; p < 0.01) and 49% (95% CI 23 to 81; p < 0.0001), respectively.
The available evidence suggests that ibuprofen 200 and 400 mg are effective in reducing headache intensity and rendering patients pain-free at 2 hours. Photophobia and phonophobia improved with 400 mg dosing. Due to the limited data and the shortcomings of the available evidence, further studies are needed.
阿司匹林和布洛芬等非甾体抗炎药已被证明对治疗偏头痛有效。
评估低剂量布洛芬治疗急性偏头痛发作的疗效。
通过电子检索(MEDLINE、EMBASE、循证医学综述和考克兰图书馆)检索截至2006年11月的临床试验,并对相关文章进行历史检索。纳入标准为:(1)双盲、随机、安慰剂对照试验,评估布洛芬片对16岁以上中度或重度偏头痛发作患者的疗效;(2)评估至少一次偏头痛发作;(3)报告2小时时头痛缓解、无痛、持续无痛或其他偏头痛相关症状缓解情况。使用的医学主题词检索词为偏头痛障碍、头痛、血管性头痛、布洛芬、成人和临床试验。随后使用偏头痛、头痛和头痛作为关键词进行关键词检索。还浏览了相关文章的参考文献列表以确定可能已发表的试验。无语言限制。两位作者独立提取数据。分歧通过讨论解决。
在中度或重度偏头痛发作的成人中,200毫克和400毫克布洛芬在减轻疼痛强度和2小时内消除疼痛(无痛)方面比安慰剂更有效。对于200毫克剂量,缓解头痛的治疗所需人数为8(95%可信区间5至20),无痛的治疗所需人数为13(95%可信区间8至50)。400毫克布洛芬缓解头痛和无痛的风险比分别为1.89(95%可信区间1.45至2.46;p<0.0001)和2.15(95%可信区间1.24至3.73;p = 0.0063)。布洛芬24小时持续无痛的结果并不比安慰剂好。400毫克布洛芬使畏光和畏声缓解的几率分别增加30%(95%可信区间8至57;p<0.01)和49%(95%可信区间23至81;p<0.0001)。
现有证据表明,200毫克和400毫克布洛芬在减轻头痛强度和使患者在2小时时无痛方面有效。4(此处原文有误,应为400)毫克剂量可改善畏光和畏声症状。由于数据有限和现有证据存在不足,需要进一步研究。